Study of Tofacitinib in Refractory Dermatomyositis

Phase 1 Completed 10 enrolled Johns Hopkins University Pfizer · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to obtain preliminary data regarding the safety and efficacy of Janus kinase (JAK) inhibitor, tofacitinib, in adults with active, treatment-refractory dermatomyositis.

Timeline

Start: 2017-01
Primary completion: 2020-09-30
Completion: 2020-09-30

Outcome

Met primary endpoint

paper At 12 weeks, the primary outcome was met in all 10 subjects. PMID 33258553 ↗

Publications

Paik JJ, Casciola-Rosen L, Shin JY, Albayda J, Tiniakou E, Leung DG, Gutierrez-Alamillo L, Perin J, Florea L, Antonescu C, Leung SG, Purwin G, Koenig A, Christopher-Stine L. Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients. Arthritis Rheumatol. 2021 May;73(5):858-865. doi: 10.1002/art.41602. Epub 2021 Mar 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tofacitinib	Small molecule	11 mg	Oral